![](/img/cover-not-exists.png)
PCN17 ONCOLOGY DRUGS GAINING FDA APPROVAL FOR LOW SURVIVAL INDICATIONS AND ENTERING FIRST TO MARKET ARE ASSOCIATED WITH LESS MATURE CLINICAL DATA COMPARED TO LATER ENTRANTS
Shohet, S., Schmetz, A., Ansart, S., Feuilly, M., Shah, S., Hollywood, A., Laughlin, W.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.141
Date:
May, 2019
File:
PDF, 706 KB
english, 2019